A carregar...
Nilotinib – Differentiating the Hope from the Hype
We discuss a report in the current issue on clinical and biochemical findings from a safety trial using the cAbl tyrosine kinase inhibitor Nilotinib (150 mg or 300 mg given daily for 24 weeks) in a small group of patients with either advanced Parkinson’s disease or Dementia with Lewy Bodies. Despite...
Na minha lista:
| Publicado no: | J Parkinsons Dis |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
IOS Press
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5044778/ https://ncbi.nlm.nih.gov/pubmed/27434298 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/JPD-160904 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|